One year after the release of Latin America’s first vaccine against COVID-19manufactured jointly between Argentina and Mexico, the authorities of the regulatory agencies ANMAT and COFEPRIS (Federal Commission for Protection against Sanitary Risk) celebrate the regulatory cooperation that allows them to carry out its production.
In a memorial ceremony, the two agencies organized a joint celebration of the first anniversary of the release of the SARS CoV-2 vaccine from AstraZeneca.
The event, which took place normally, was attended by officials from regulatory agencies from other countries on the continent, such as Canada, Cuba, Chile, Guatemala, Nicaragua, Peru and Uruguay, among others. Similarly, there were representatives of Pan American Health Organization (PAHO).
The meeting was opened by Manuel Limeres, national administrator of ANMAT, who highlighted the work done together with COFEPRIS, which resulted in the production of “a safe vaccine for our people”.
For his part, the head of the Mexican agency, Alejandro Svarch, emphasized “regulatory solidarity” between peer agencies to produce “a safe, efficient and high-quality biological product”, while at the same time providing strategic support to OPS. value. in the vaccine validation process.
In December 2021, the vaccines mAbxience (Argentina) and Liomont (Mexico) were produced as 11th vaccine on the list of emergency uses validated by the WHO and as the first in Latin America. According to the Mexican Ministry of Health, COFEPRIS has released more than 100 batches of vaccines, equivalent to more than 85 million doses distributed in several countries in the region.